Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD

NCT04757610 is registered in ClinicalTrials.gov with Opthea Limited as lead sponsor.

NCT NCT04757610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04757610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicentre, Double-masked, Randomised Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With nAMD
Lead sponsor
Opthea Limited
Phase
Phase 3
Overall status
Terminated
Start date
March 12, 2021
Completion date
March 31, 2025
Enrollment
986 (actual)
Sites
191

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration